Breast Cancer
New breast cancer research has been reported by scientists at Indiana University
Published in Drug Law Weekly, January 12th, 2010
"Enzastaurin is a potent, serine-threonine kinase inhibitor which selectively targets PKC beta and PI3K/AKT signaling pathways to reduce cell proliferation, induce apoptosis, and inhibit angiogenesis. As PKC beta and PI3K/AKT signaling are both involved in breast cancer pathogenesis, this phase II study evaluated the efficacy and toxicity of enzastaurin in previously treated patients with metastatic breast cancer (MBC)," scientists writing in the journal Investigational New Drugs report.
"Eligible patients had histologically confirmed MBC with measurable disease, and must have received prior anthracycline and taxane chemotherapy, but not more than two prior...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
Source: Drug Law Weekly (2010-01-12)
More Articles from Drug Law Weekly
- Adventrx Pharmaceuticals Inc.
ADVENTRX Pharmaceuticals Announces Financing - Clinical Trial Research
New findings reported from University of Nottingham describe advances in clinical trial research - Coalition for Pulmonary Fibrosis
Coalition for Pulmonary Fibrosis Celebrates Successes Despite Year of Economic Downturn - CSL Behring
CSL Behring Awards Fourth Round of LEAD Grants Supporting Patient Organization Advocacy - Life Sciences
New life sciences research reported from Cornell University - Life Sciences
Scientists at University of Otago publish new data on life sciences - More from this issue of Drug Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
